Novel antihypertensive agents

Bibliography

• ISLES CG, WALKER LM, BEEVERS GD,BROWN I, CAMERON HL, CLARKE J et al.: Mortality in patients of the Glasgow Blood Pressure Clinic. Hypertens. (1986) 4:141–156.
   Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG, DALHOF B, ELMFELDT D, JULIUS S et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• ANDERSON OK, ALMGREN T, PERSSON B, SAMUELSSON 0, HEDNER T, WILHELMSEN L: Survival in treated hypertension: follow-up study after two decades. Br. Med. J. (1998) 317:167–171.
   PubMedGoogle Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR, CUSHMAN WC, LA, IZZO JL Jr et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 289:2560–2572.
   PubMed Web of Science ®Google Scholar
• ••The more recent American Guidelines totreat high BE
   Google Scholar
• 2003 EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: 2003 European Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial hypertension:.! Hypertens. (2003) 21:1011–1053.
   Google Scholar
• ••The more recent European Guidelines totreat high BE
   Google Scholar
• BURT VL, CUTLER JA, HIGGINS M, HORAN MJ, LABARTHE D, WHELTON P et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension (1995) 26:60–69.
   Google Scholar
• PRIMATESTA P, BROOKES M, POULTER NR: Improved hypertension management and control: results from the survey for England 1998.Hypertension (2001) 38:827–832.
   PubMed Web of Science ®Google Scholar
• RUILOPE LM, COCA A, VOLPE M, WAEBER B: ACE inhibition and cardiovascular morbidity and mortality in essential hypertension: the end of the search or a need for further investigations. Am. J. Hypertens. (2002) 15:367–371.
   PubMed Web of Science ®Google Scholar
• LIP GY, BEEVERS DG: More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPETOO AND SYST-EUR2). I Hum. Hypertens. (2003) 17:747–750.
   PubMed Web of Science ®Google Scholar
• WEBER MA, WHITE WB: Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes? Blood Press. Monit. (2003) 8:215–22.
   Google Scholar
• WEIR MR, WEBER MA, NEUTEL JM, VENDETTI J, MICHELSON EL, WANG RY: Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am. Hypertens. (2001) 14:567–572.
   PubMed Web of Science ®Google Scholar
• ALDERMAN MH, MADHAVAN S, 001 WL, COLEN H, SEALEY JE, LARAGH JH: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl. Med. (1991) 324:1098–1104.
   PubMed Web of Science ®Google Scholar
• BURNIER M, BRUNNER HR: Angiotensin II receptor antagonists. Lancet (2000) 355:637–645.
   PubMed Web of Science ®Google Scholar
• VOLPE M, MUSUMECI B, PAOLIS P, SAVOIA C, MORGANTI A: Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?. (2003) 21:1429–1443.
   Google Scholar
• DAHLOF B, DEVEREUX RB, SE, JULIUS S, BEEVERS G, DE FAIRE et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• MANN J, JULIUS S: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. (1998) 7:176–183.
   PubMedGoogle Scholar
• ALLHAT OFFICERS AND FOR THE ALLHAT RESEARCH GROUP: The Antihypertensive and lipid-lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). JA/VIA (2002) 288:2981–2997.
   Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L, LANKE J, HEDNER T, NIKLASON A et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl. Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• VIBERTI G, WHEELDON NM; Microalbuminuria Reduction With Valsartan (MARVAL) Study Investigators: microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 106:672–678.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSIKER LG, WR, BERL T, POHL MA, LEWIS JB et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. J. Med. (2001) 345:851–860.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D, KEANE WF, WE, PARVING HH et al: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. I Med. (2001) 345:861–869.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G, VALSARTAN HEART FAILURE TRIAL INVESTIGATORS: arandomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. I Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, McMURRAY JJ, YUSUF S, HELD P, MICHELSON EL, OLOFSSON B et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• McMURRAY JJ, OSTERGREN J, K, GRANGER CB, HELD P, MICHELSON EL et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767–771.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, SWEDBERG K, GRANGER CB, HELD P, JJ, MICHELSON EL et al: of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. (2003) 362:759–766.
   Google Scholar
• PFEFFER MA, McMURRAY JJ, VELAZQUEZ EJ, ROULEAU JL, KOBER L, MAGGIONI AP: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. I Med. (2003) 349:1893–1906.
   PubMed Web of Science ®Google Scholar
• NAKAO N, YOSHIMURA A, H, TAKADA M, KAYANO T, IDEURA T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (2003) 361:117–124.
   PubMed Web of Science ®Google Scholar
• WIKLUND I, HALLING K,-BERGSTEN T, FLETCHER A: Does lowering the blood pressure improve the mood? Quality-of-life results from the Optimal Treatment (HOT). Blood Press. (1997) 6:357–364.
   PubMedGoogle Scholar
• WEBER MA, BAKRIS GL, NEUTEL JM, DAVIDAI G, GILES TD: Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.. Hypertens. (2003) 5:322–329.
   Google Scholar
• BLOOM BS: Continuation of initial antihypertensive medication after 1 year of therapy. Clin. The]: (1998) 20:671–681.
   Google Scholar
• CONLIN PR, GERTH WC, FOX J, ROEHM JB, BOCCUZZI SJ: Four-year persistence patterns among patients therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin. Thei: (2001) 23:1999–2010.
   Google Scholar
• •This article shows the long-term adherence to ARBs.
   Google Scholar
• BERCK BC, VEKSTEIN V, HM, TSUDA T: Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension (1989) 13:305–314.
   PubMed Web of Science ®Google Scholar
• GRIENDLING KK, MINIERI CA, OLLERENSHAW JD, ALEXANDER RW: Angiotensin II stimulates NADH and NADPH wddase activity in cultured vascular smooth muscle cells. Circ. Res. (1994) 74:1141–1148.
   PubMed Web of Science ®Google Scholar
• VAUGHAN DE, LAZOS SA, TONG K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J. Clin. Invest. (1995) 95:995–1001.
   PubMed Web of Science ®Google Scholar
• BRILLA C, WEBER K: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc. Res. (1992) 26:671–677.
   PubMed Web of Science ®Google Scholar
• ROCHA R, CHANDER C, KHANNA K, ZUCKERMAN A, STIER C: blockade reduces vascular injury in stroke-prone hypertensive rats. (1998) 31:451–458.
   Google Scholar
• TADDEI S, VIRDIS A, MATTEI P, SALVETTI A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension (1993) 21:929–933.
   PubMed Web of Science ®Google Scholar
• BLACHER J, AMAH G, GIRERD X, KLEDER A, BEN MAIS H, GM et al: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am. J. Hypertens. (1997) 10:1326–1334.
   PubMed Web of Science ®Google Scholar
• BROWN NJ, AGIRBASLI MA, WILLIAMS GH, LITCHFIELD WR, VAUGHAN DE: Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I. Hypertension (1998) 32:965–971.
   PubMed Web of Science ®Google Scholar
• DELYANI JA: Mineralcorticoid receptorantagonists: the evolution of utility and pharmacology. Kidney Int. (2000) 57:1408–1411.
   PubMed Web of Science ®Google Scholar
• FUNDER J: New biology of aldosterone,and experimental studies on the selective aldosterone blocker eplerenone.. Heart J. (2002) 144:S8–S11.
   PubMed Web of Science ®Google Scholar
• •A review about the vascular effects of aldosterone.
   Google Scholar
• PITT B, REMME W, ZANNAD F, NEATON J, MARTINEZ F, RONIKER B et al.: for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators. New Engl J. Med. (2003) 348:1309–1321.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME W, CODY R, CASTAIGNE A, PEREZ A et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• CORVOL P, MICHAUD A, MENARD J, FREIFELD M, MAHOUDEAU J: effect of spironolactone: mechanism of action. Endocrinology (1975) 97:52–58.
   PubMed Web of Science ®Google Scholar
• STAESSEN J, LUNEN P, FAGARD R, VERSCHUEREN LV, AMERY A: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. (1981) 91:460–465.
   Google Scholar
• STRUTHERS AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.. Card. Fail. (1996) 2:47–54.
   PubMedGoogle Scholar
• YOUNG WF Jr: Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology (2003) 144:2208–2213.
   PubMed Web of Science ®Google Scholar
• DE GASPARO M, JOSS U, RAMJOUE S, WHITEBREAD SE, HAENNI H, SCHENKE L et al.: Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. j Pharinacol Exp. Ther. (1987) 240:650–656.
   PubMed Web of Science ®Google Scholar
• LARAGH JH, SEALY JE: K(*) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. (2001) 37:806–810.
   Google Scholar
• SHEP COOPERATIVE RESEARCH GROUP: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly program (SHEP). JAMA (1991) 265:3255–3264.
   PubMed Web of Science ®Google Scholar
• WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. Hypertens. (2002) 15:709–716.
   PubMed Web of Science ®Google Scholar
• WHITE WB, DUPREZ D, RS, KRAUSE S, RONIKER B, KUSE-HAMILTON J et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41:1021–1026.
   PubMed Web of Science ®Google Scholar
• PITT B, REICHEK N, R, ZANNAD F, PHILLIPS RA, RONIKER B et al.: Effects of eplerenone, enalapril, and eplerenone/ enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation (2003) 108:1831–1838.
   Google Scholar
• SAMARAS K, CAMPBELL LV: Increasing incidence of Type 2 diabetes in the third millennium: is abdominal fat the central issue? Diabetes Care (2000) 23:443–444.
   Google Scholar
• SAMARAS K, ARDEN N, KELLY PJ, SPECTOR TD, CHIANO MN, CAMPBELL LV: Genes versus environment. The relationship between dietary fat and total and central abdominal fat. Diabetes Care (1998) 21:2069–2076.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE: Rationale for and role ofthiazolidinediones in Type 2 diabetes mellitus. Am. Cardiol (2002) 90:34G–41G.
   Google Scholar
• •This paper summarises the vascular effects of thiazolidinediones.
   Google Scholar
• NARAYAN KMV, BOYLE JP, THOMPSON TJ, SORENSEN SW, WILLIAMSON DF: Lifetime risk for diabetes mellitus in the United States. JAMA (2003) 290:1884–1890.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, AMIRI F, K, IGLARZ M, DIEP QN: Perwdsome proleferator -activated receptors. Vascular and cardiac effects in hypertension. Hypertension (2003) 42:664–668.
   PubMedGoogle Scholar
• LEBOVITZ HE, BANERJI MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Holm. Res. (2001) 56:265–294.
   PubMedGoogle Scholar
• LEBOVITZ HE, DOLE JF, R, RAPPAPORT EB, FRIED MI, AND THE ROSIGLITAZONE CLINICAL TRIALS STUDY GROUP: Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. I Clin. Endocrinol Metab. (2001) 86:280–288.
   PubMed Web of Science ®Google Scholar
• RAJI A, SEELY EW, BEKINS SA, WILLIAMS GH, SIMONSON DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care (2003) 26:172–178.
   PubMed Web of Science ®Google Scholar
• DOBRIAN AD, SCHRIVER SD, KHRAIBI AA, PREWITT RL: Pioglitazone prevents hypertension and reduces oxidative stress in diet induced obesity. Hypertension (2004) 43:48–56.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, LEHTO S, T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with Type 2 diabetes mellitus and in nondiabetic subjects with and without prior myocardial infarction. N Engl. I Med. (1998) 339:229–234.
   PubMed Web of Science ®Google Scholar
• FULLER JH, SHIPLEY MJ, ROSE G, JARRET RJ, KEEN H: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall Study. Lancet (1980) 1:1373–1376.
   PubMed Web of Science ®Google Scholar
• SMITH NL, BARZILAY JI, SHAFFER D,SAVAGE PJ, HECKBERT SR, LH et al.: Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch. Intern. Med. (2002) 162:209–216.
   Google Scholar
• MEIGS JB, NATHAN DM, D'AGOSTINO RB Sr, WILSON PW; Framingham Offspring Study: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care (2002) 25:1845–1850.
   PubMed Web of Science ®Google Scholar
• COUTINHO M, GERSTEIN HC, WANG Y, YUSUF S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 22:233–240.
   Google Scholar
• TUOMILEHTO J, LINDSTROM J, ERIKSSON JG, VALLE TT, HAMALAINEN H, ILANNE-PARIKKA P et al.: Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl. Med. (2001) 344:1343–1350.
   Google Scholar
• KNOWLER WC,-CONNOR E, FOWLER SE, for the Diabetes Prevention Program Research Group: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl. Med. (2002) 346:393–403.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, XIANG AH, RK, KJOS SL, MARROQUIN A, GOICO J et al.: Preservation of pancreatic 13-cell function and prevention Type 2 diabetes by pharmachological treatment of insulin resistance in high risk Hispanic women. Diabetes (2002) 51:2796–2803.
   PubMed Web of Science ®Google Scholar
• CHIASSON JL, JOSSE RG, GOMIS R,HANEFELD M, KARASIK A, M: Acarbose for prevention of Type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet (2002) 359:2072–2077.
   PubMed Web of Science ®Google Scholar
• CHIASSON JL, JOSSE RG, GOMIS R, M, KARASIK A, M, STOP-NIDDM TRIAL RESEARCH GROUP: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA (2003) 290:486–494.
   PubMed Web of Science ®Google Scholar
• •This article shows the benefit of acarbose in reducing BP.
   Google Scholar
• CERIELLO A, BORTOLOTTI N, MOTZ E, CRESCENTINI A, LIZZIO S, RUSSO A et al.: Meal generated oxidative stress in Type 2 diabetic patients. Diabetes Care (1998) 21:1529–1533.
   PubMed Web of Science ®Google Scholar
• HEITZER T, SCHLINZIG T, KROHN K, MEINERTZ T, MUNZEL T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 104:2673–2678.
   PubMed Web of Science ®Google Scholar
• DESPRES JP, MOORJANI S, LUPIEN PJ, TREMBLAY A, NADEAU A, BOUCHARD C: Regional distribution of body fat, lipoproteins, and cardiovascular disease. Arteriosclerosis (1990) 10:497–511.
   PubMedGoogle Scholar
• DESPRES JP, TREMBALY A, THERIAULT G, PERUSSE L, LEBLANC C, BOUCHARD C: Relationships between body fatness, adipose tissue distribution and blood pressure in men and women. j. Clin. Epideiniol (1988) 41:889–897.
   PubMed Web of Science ®Google Scholar
• NEATON JD, BLACKBURN H, JACOBS D, KULLER L, LEE DJ, SHERWIN R et al.: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. (1992) 152:1490–1500.
   Google Scholar
• MARON DJ, FAZIO S, LINTON MF: Current perspectives on statin. Circulation (2000) 101:207–213.
   PubMed Web of Science ®Google Scholar
• GOODE GK, MILLER JP, HEAGERTY AM: Hyperlipidemia, hypertension, and coronary heart disease. Lancet (1995) 345:362–364.
   PubMed Web of Science ®Google Scholar
• BORGHI C, VERONESI M, MG, DORMI A, AMBROSIONI E: Statins and blood pressure regulation. Carr: Hypertens. Rep. (2001) 3:281–288.
   PubMedGoogle Scholar
• ••A review of interest about statins and BPregulation.
   Google Scholar
• GLORIOSO N, TROFFA C, F, DETTORI F, SORO A, PARPAGLIA P et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension (1999) 34:1281–1286.
   PubMed Web of Science ®Google Scholar
• IDE H, FUJIYA S, AANUMA Y, AGISHI Y: Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin. Thec (1990) 12:410–420.
   PubMed Web of Science ®Google Scholar
• TONOLO G, MELTS MG, FORMATO M, ANGIUS ME CARBONI A, BRIZZI P et Additive of Simvastatin beyond its effects on LDL cholesterol in hypertensive Type 2 diabetic patients. Eui: Clin. Invest. (2000) 30:980–987.
   Google Scholar
• SPOSITO AC, MANSUR AP, OR, NICOLAU JC, JA: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). ilm.j Cardiol (1999) 83:1497–1499.
   PubMed Web of Science ®Google Scholar
• •This is the first published paper reporting a possible pharmacodynarnic interaction between statins and antihypertensive drugs.
   Google Scholar
• BORGHI C, PRANDIN MG, COSTA FV, BACHELLI S, DEGLI ESPOSTI D, AMBROSIONI E: Use of statins and blood pressure control in hypertensive patients with hypercholesterolemia. Cardiovasc. Phannacol (2000) 35:549–555.
   PubMed Web of Science ®Google Scholar
• LAUFS U, LA FATA V, PLUTZKY J, LIAO JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase. Circulation (1998) 97:1129–1135.
   PubMed Web of Science ®Google Scholar
• NICKENIG G, BAUMERAT, TEMURY, KEBBEN D, JOCKENHOVEL F, BOHM M: Statin-sensitive dysregulated ATi receptor function and density in hypercholesterolemic men. Circulation (1999) 100:2131–2134.
   PubMed Web of Science ®Google Scholar
• LAW MR, WALD NJ, RUDNICKA AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med. (2003) 326:1423–1429.
   PubMed Web of Science ®Google Scholar